Development and Characterization of Modified Release Tablet Etodolac with Proteolytic Enzyme Serratiopeptidase

Abstract

Abstract: Developing and characterizing a modified-release tablet is the main goal of this project which contains Etodolac, a selective NSAID, and Serratiopeptidase, a proteolytic enzyme known for its anti-inflammatory and fibrinolytic properties. The objective is to design a formulation that provides modified drug release, reduces gastrointestinal side effects, and enhances therapeutic efficacy. A polymer-based matrix system was utilized to control drug release, and various formulation strategies were employed to optimize the tablet composition. Stability studies, in vitro drug release profiles, and physicochemical parameters were used to assess the created formulation. These results demonstrated that the modified-release tablet maintained consistent drug levels over an extended period, improving patient compliance and minimizing side effects. The synergistic action of Etodolac and Serratiopeptidase offers a promising alternative for managing chronic inflammatory conditions, paving the way for further research into advanced drug delivery systems.